Las Vegas, NV -- (SBWIRE) -- 01/27/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: CYS Investments Inc (NYSE:CYS), ShoreTel, Inc. (NASDAQ:SHOR), Gafisa SA (ADR)(NYSE:GFA), Nektar Therapeutics (NASDAQ:NKTR)
CYS Investments Inc (NYSE:CYS) managed to keep its gain at 0.63% on below -normal volume of 2.90M shares. The stock settled at $7.94 after floating in a range of $6.74 to $13.08. Its latest price has reached market capitalization of $1.33 billion. Its 52-week range has been $7.88 to $7.98. CYS Investments, Inc. is a specialty finance company created with the objective of achieving consistent risk-adjusted investment income.
For How Long CYS will fight for Profitability? Read This Trend Analysis report
ShoreTel, Inc. (NASDAQ:SHOR) traded down on a volume of 2.30 million, higher than its standard daily volume. Shares have dropped -11.50% to $8.31. Over the last twelve months, the stock has gained 70.99% and faced a worst price of $3.25. ShoreTel, Inc. is a provider of business communication solutions. The Company’s unified communications (UC) and contact center solutions are based on its Internet protocol (IP) business phone system (IP-PBX). It offers organizations of all sizes integrated voice, video, data and mobile communications on an open, distributed IP architecture and switch-based hardware platform, which enable multi-site enterprises to be served by a single system.
Has SHOR Found The Bottom And Ready To Gain Momentum? Find Out Here
Gafisa SA (ADR)(NYSE:GFA) settled -4.53% lower at $2.74 on above-normal volume of 2.30M shares during the last trading day. The stock has its 12-month high at $5.20 and 52-week low price was $2.22. It traded in a range of $2.70 to $2.77 during the last trading day. Gafisa SA is a Brazil-based company engaged in the homebuilding and real estate operations.
Will GFA Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Nektar Therapeutics (NASDAQ:NKTR) was down on high volume, trading at a volume of 2.28M versus its average daily volume of 973,724.00 shares. At $12.92, the stock has attained market capitalization of 1.61 billion. Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.
Why Should Investors Buy NKTR After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)